|Bid||0.00 x 2200|
|Ask||0.00 x 900|
|Day's Range||41.87 - 42.42|
|52 Week Range||31.56 - 43.66|
|Beta (3Y Monthly)||0.70|
|PE Ratio (TTM)||42.58|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.
This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...
Cerevel announced Wednesday that Bain Capital principal Orly Mishan has moved from a space on the company's board of directors to become its new chief business officer.
Within MedSurg, Boston Scientific (BSX) is on track for the year-end launch of Exalt-D Single-Use Duodenoscope, which is used in ERCP procedures.
Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Mayo Clinic and Boston Scientific Corp. on Monday will announce the formation of Motion Medical, a medical-technology accelerator housed in Rochester's new Destination Medical Center development.
Today we'll evaluate Boston Scientific Corporation (NYSE:BSX) to determine whether it could have potential as an...
Boston Scientific and Thermo Fisher Scientific stocks tripped Wednesday after the medtech companies beat second-quarter earnings forecasts, but reported roughly in-line revenue.
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and -0.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific Corp. reported second-quarter profit Wednesday that topped Wall Street expectations, though the company missed analysts' estimates on revenue. Profit for the latest quarter fell to $154 million, or 39 cents a share, from $555 million, or 41 cents a share, in the year-earlier quarter. Adjusted EPS fell to 39 cents from 41 cents a year ago, but topped the FactSet consensus of 38 cents. Revenue rose 5.6% to $2.63 billion from $2.49 billion a year ago, just falling short of the FactSet consensus of $2.64 billion. Sales of the company's MedSurg segment grew 9% to $818 million, while the sales of the rhythm and neuro business grew 1.4% to $786 million. Revenue from the cardiovascular unit grew 6.3% to $1.026 billion. The company lowered its full-year EPS guidance to between 94 cents and 98 cents a share from its previous guidance of between $1.09 and $1.13 a share. Adjusted earnings should still be $1.54 to $1.58 a share, the company said, consistent with prior guidance. Shares of Boston Scientific were down 0.3% in premarket trade on Wednesday. The company's stock has gained 21.3% in the year to date through Tuesday, while the S&P 500 has gained 19.9%.
Boston Scientific Corp narrowly beat Wall Street estimates for quarterly profit on Wednesday, helped by higher sales of its surgical products used to treat urological and pelvic conditions. "Expectations were for higher than 6.3% organic growth – solid results, but did not meet high expectations," Cowen and Co analyst Joshua Jennings said. Earlier this year, the U.S. Food and Drug Administration had raised safety concerns about balloons and stents coated with a paclitaxel drug used to treat peripheral arterial disease, including Boston Scientific's Eluvia system.
This Peninsula company reported strong results from a late-stage clinical trial of its experimental treatment for women who suffer from heavy bleeding and pain due to uterine fibroids. But potential competition from a biopharma giant may be keeping investor enthusiasm in check.
Boston Scientific Corp. is expected to report net income of $535 million, or 38 cents a share, on sales of $2.6 billion before the market opens on Wednesday, based on a FactSet survey of 22 analysts. It reported net income of $298 million. The company offered guidance of 37 cents a share to 39 cents a share at the time of its last earnings report on April 24.
We are upbeat about solid contributions from Boston Scientific's (BSX) Cardiovascular business group, which comprises Interventional Cardiology and Peripheral Interventions.
In the wake of the U.S. tariff and Chinese retaliation, the MedTech industry players (with production houses in China) are facing huge bottom line pressure.